HCPCS Level II code J0222 denotes the injectable biologic patisiran measured per 0.1 mg. Patisiran is a therapy used for hereditary transthyretin-mediated amyloidosis and related clinical indications; accurate reporting with J0222 supports clinical documentation, drug utilization tracking, and payer processing for high-cost specialty pharmaceuticals. Nationally, clear use of this HCPCS Level II code matters because specialty infusions drive significant outpatient drug spending and require consistent coding to align clinical intent, benefit eligibility, and medical necessity review.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact briefing on what J0222 represents, typical sites where the service is delivered, and the practical implications for billing workflows. The publication summarizes reimbursement benchmarks, payer policy considerations, and coding nuances tied to injectable specialty therapies. Clinicians and billing professionals will gain a concise reference for documentation expectations, claim submission context, and topics to monitor such as policy updates and coverage criteria. Data not available in the input is noted where applicable.